Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted ratesAgreement provides Johnson & Johnson pharmaceutical products an exemption from U.S.
Series C funding to accelerate the clinical and industrial development of FlowMaker®€48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in middle-market industrial and ...
Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively1,318 patient start forms received in ...
Investor Day on January 21, 2026, to present new product vision and AI solutionsRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company” ...
The Global Agri-Food Advancement Partnership (GAAP) is pleased to announce the signing of a Memorandum of Understanding (MOU) ...
VANCOUVER, BC / ACCESS Newswire / January 8, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: ...
Pfizer collaboration applies Gordian’s large-scale in vivo mosaic screening platform to prioritize novel obesity targets directly within visceral adipose tissueSAN FRANCISCO--(BUSINESS WIRE)--#biotech ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent ...
The "Tanzania Glucose Syrup Market | Emerging Trends, Shares, Investment Opportunities and Competitive Intelligence" has been added to ResearchAndMarkets.com's offering.Projected to grow at a CAGR of ...
Phase 1 proof-of-concept study of CLY-124 in Sickle Cell Disease expected in Q4 2026In vivo preclinical data assessing new compounds vs. standard of care in gold-standard, translatable myelofibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback